Payment overview · 2025
General Payments
$747.07
31 reported records · 12 companies
Healthcare provider profile · identity verified
Alexander Beker
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1588712152
Verified facts
What the public records show
CMS Open Payments records show Alexander Beker received $747.07 in general payments during 2025 across 31 reported records.
GlaxoSmithKline, LLC. accounted for 23.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Jardiance, Prolia, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 333 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 311 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Prolia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synjardy by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 251 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 251 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $173.07 | 23.2% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $122.10 | 16.3% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $99.08 | 13.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $61.13 | 8.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $60.71 | 8.1% | 3 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $54.71 | 7.3% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $54.56 | 7.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.17 | 3.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $26.67 | 3.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $23.68 | 3.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.65 | 3.2% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $19.54 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $747.07 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $173.07 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $88.92 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $66.73 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $61.13 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $61.13 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $60.71 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $59.85 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $59.85 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $59.85 | 3 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $54.71 | 2 | 2025 |
Source payment records
|
|||||
| ECC Solutions Normalized: ecc solutions |
Device | Philips North America LLC | $54.56 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $40.35 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $37.82 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $32.35 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $28.17 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $23.68 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 251 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 60 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 192 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 17 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 51 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
157 | 33 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
333 | 47 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
311 | 44 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
17 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
192 | 33 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
251 | 41 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
51 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
251 | 41 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 990 | 166 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 899 | 154 |
| Atorvastatin Calcium | Atorvastatin Calcium | 706 | 128 |
| Metoprolol Succinate | Metoprolol Succinate | 660 | 120 |
| Losartan Potassium | Losartan Potassium | 554 | 103 |
| Omeprazole | Omeprazole | 550 | 103 |
| Tamsulosin Hcl | Tamsulosin Hcl | 413 | 66 |
| Metformin Hcl | Metformin Hcl | 342 | 60 |
| Simvastatin | Simvastatin | 335 | 45 |
| Linzess | Linaclotide | 333 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 327 | 55 |
| Synthroid | Levothyroxine Sodium | 311 | 44 |
| Carvedilol | Carvedilol | 300 | 51 |
| Gabapentin | Gabapentin | 283 | 53 |
| Vascepa | Icosapent Ethyl | 278 | 51 |
| Furosemide | Furosemide | 264 | 64 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 256 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 253 | 45 |
| Eliquis | Apixaban | 251 | 41 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 250 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 236 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 230 | 56 |
| Allopurinol | Allopurinol | 225 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 214 | 45 |
| Glimepiride | Glimepiride | 203 | 37 |
| Jardiance | Empagliflozin | 192 | 33 |
| Lisinopril | Lisinopril | 185 | 32 |
| Famotidine | Famotidine | 183 | 31 |
| Ezetimibe | Ezetimibe | 180 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 177 | 35 |
| Atenolol | Atenolol | 171 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 171 | 29 |
| Donepezil Hcl | Donepezil Hcl | 166 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 164 | 28 |
| Enalapril Maleate | Enalapril Maleate | 163 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 160 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 158 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 158 | 22 |
| Creon | Lipase/Protease/Amylase | 157 | 33 |
| Dexlansoprazole Dr | Dexlansoprazole | 149 | 22 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 149 | 25 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 145 | 30 |
| Icosapent Ethyl | Icosapent Ethyl | 134 | 28 |
| Mirtazapine | Mirtazapine | 122 | 24 |
| Montelukast Sodium | Montelukast Sodium | 121 | 19 |
| Finasteride | Finasteride | 108 | 16 |
| Buspirone Hcl | Buspirone Hcl | 101 | 21 |
| Ibuprofen | Ibuprofen | 101 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 16 |
| Naproxen | Naproxen | 94 | 20 |
| Memantine Hcl | Memantine Hcl | 93 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 91 | 31 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 86 | 15 |
| Meloxicam | Meloxicam | 84 | 28 |
| Tramadol Hcl | Tramadol Hcl | 81 | 19 |
| Ammonium Lactate | Ammonium Lactate | 80 | 20 |
| Nitroglycerin | Nitroglycerin | 80 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 69 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 69 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | 12 |
| Celecoxib | Celecoxib | 63 | 11 |
| Metformin Hcl Er | Metformin Hcl | 62 | suppressed |
| Tradjenta | Linagliptin | 62 | suppressed |
| Xarelto | Rivaroxaban | 62 | 14 |
| Sertraline Hcl | Sertraline Hcl | 61 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 61 | 12 |
| Clonidine Hcl | Clonidine Hcl | 60 | 18 |
| Entresto | Sacubitril/Valsartan | 60 | suppressed |
| Januvia | Sitagliptin Phosphate | 60 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 60 | 16 |
| Hydrocortisone | Hydrocortisone | 59 | 23 |
| Calcitriol | Calcitriol | 58 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 58 | 11 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 57 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 57 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 23 |
| Valsartan | Valsartan | 55 | 11 |
| Alprazolam | Alprazolam | 53 | suppressed |
| Colchicine | Colchicine | 53 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 53 | suppressed |
| Spironolactone | Spironolactone | 53 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 51 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | 11 |
| Alendronate Sodium | Alendronate Sodium | 50 | 12 |
| Azithromycin | Azithromycin | 50 | 44 |
| Ventolin Hfa | Albuterol Sulfate | 48 | suppressed |
| Clonazepam | Clonazepam | 47 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 44 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 44 | 18 |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 43 | suppressed |
| Nifedipine Er | Nifedipine | 43 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 41 | suppressed |
| Dutasteride | Dutasteride | 41 | suppressed |
| Glipizide Er | Glipizide | 41 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 41 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 40 | 11 |
| Trazodone Hcl | Trazodone Hcl | 39 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 30 |
| Lorazepam | Lorazepam | 35 | 11 |
| Nystatin | Nystatin | 35 | suppressed |
| Potassium Chloride | Potassium Chloride | 35 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 34 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 12 |
| Mupirocin | Mupirocin | 33 | 26 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 31 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Eszopiclone | Eszopiclone | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Lactulose | Lactulose | 31 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | suppressed |
| Telmisartan | Telmisartan | 31 | suppressed |
| Acarbose | Acarbose | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Cilostazol | Cilostazol | 30 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 30 | suppressed |
| Ozempic | Semaglutide | 30 | suppressed |
| Torsemide | Torsemide | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Ramipril | Ramipril | 29 | 11 |
| Azelastine Hcl | Azelastine Hcl | 28 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 28 | suppressed |
| Ranolazine Er | Ranolazine | 28 | suppressed |
| Ztlido | Lidocaine | 28 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 27 | suppressed |
| Repaglinide | Repaglinide | 26 | suppressed |
| Dexilant | Dexlansoprazole | 25 | suppressed |
| Methimazole | Methimazole | 25 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 25 | suppressed |
| Ursodiol | Ursodiol | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Edarbi | Azilsartan Medoxomil | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 23 | suppressed |
| Benicar | Olmesartan Medoxomil | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | 20 |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 21 | 12 |
| Primidone | Primidone | 21 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Niacin Er | Niacin | 20 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 20 | suppressed |
| Bystolic | Nebivolol Hcl | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Mupirocin | Mupirocin Calcium | 19 | suppressed |
| Clotrimazole | Clotrimazole | 18 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 18 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 17 | suppressed |
| Prolia | Denosumab | 17 | 11 |
| Synjardy | Empagliflozin/Metformin Hcl | 17 | suppressed |
| Captopril | Captopril | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Cyclosporine | Cyclosporine | 14 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Crestor | Rosuvastatin Calcium | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Proctozone-Hc | Hydrocortisone | 13 | suppressed |
| Dipyridamole | Dipyridamole | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Mitigare | Colchicine | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $747.07 · 31 records | GlaxoSmithKline, LLC. | ABRYSVO, COMIRNATY, ECC Solutions, ELIQUIS, ENTRESTO, EVENITY, JARDIANCE, Kerendia, LEQVIO, NURTEC ODT, PREVNAR 20, PROLIA, PYRUKYND, QULIPTA, TRELEGY ELLIPTA, UBRELVY, VERQUVO | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error